Pfizer's key messages at JP Morgan conference
Last week, US pharma giant Pfizer (NYSE: PFE) chairman and chief executive Albert Bourla presented at the JP Morgan Healthcare Conference in San Francisco.
During the fireside chat, Dr Bourla highlighted Pfizer's performance in 2025 and outlined its four strategic priorities for 2026. Some key messages and takeaways include that 2025 was a year of successful execution, marked by beating expectations for revenue and profitability over the last three consecutive quarters.
Pfizer successfully improved margins by removing $5.6 billion in OpEx between 2024 and 2025. The company also resolved major policy overhangs including MFN (Most Favored Nation) pricing and tariffs, while also providing clarification on its obesity strategy through key business transactions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze